Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pharmaxis Ltd receives approval for use of Bronchitol in Cystic Fibrosis Patients from Scotland


Monday, 9 Dec 2013 11:15pm EST 

Pharmaxis Ltd:Says the Scottish Medicines Consortium has accepted Bronchitol for use by the National Health Service in Scotland. Bronchitol is licensed fro the treatment of adult cystic fibrosis(CF) patients aged 18 years and above. 

Company Quote

0.175
0.015 +9.38%
17 Apr 2015